1. Do we need to separate iNKT cells using certain positive markers, like Vα24 TCRα and CD1d, or negative markers, like CD8, before we can use them in a clinical setting?
2. Should the α-GalCer pulsed APC be grown along with the iNKT cells, or can a certain amount of α-GalCer be added to the PBMCs all the time to selectively stimulate and grow iNKT cells?
3. Is it necessary to apply irradiated autologous PBMCs to the potential clinical production of iNKT cells?
- Badges
- Science topic
- Similar topics
- Biological Science
- Immunology
- Antibodies
More Yu Yu's questions See All
Similar questions and discussions